Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG-M131 in TRBC1-positive Relapsed/Refractory Peripheral T-cell Lymphoma
NCT07758491Phase 2Not yet recruiting
- Sponsor
- Beijing Mingzhi Zhishan Biotechnology
- Start
- Aug 2026
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
A Phase 2 trial of FG-M131 in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), sponsored by Beijing Mingzhi Zhishan Biotechnology. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
FG-M131
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07758491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758491.